RCS - ReNeuron Group plc - Investor presentations

ReNeuronAnnouncement

25/02/2021 07:05

RNS Number : 2561Q
  
ReNeuron Group plc
  
25 February 2021
  
 

ReNeuron Group plc
("ReNeuron" or the "Company")
 
Investor presentations 
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces it will be presenting at three investor events, providing an overview of the business and the progress being made by the Company as it focuses on its retinal disease programme and exosome and iPSC platforms.
 
Proactive One2One Investor Forum
ReNeuron will present at today's Proactive One2One Investor Forum, commencing at 6.00pm, with ReNeuron presenting at this time. The event brings together high net worth investors and private investors with an interest in growth stocks. Investors can register to attend the event here: 
https://www.proactiveinvestors.co.uk/register/event_details/319
 
Shares Investor Evening Webinar 
ReNeuron will present at the Shares Investor Evening Webinar, on Tuesday 2 March 2021. Shares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for investors to ask questions. The event will commence at 6.00pm and ReNeuron will present at 6.55pm. Investors can register to attend the event here: https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-020321
 
H.C. Wainwright Global Life Sciences Conference 
The Company will present at the H.C. Wainwright Global Life Sciences Virtual Conference which is taking place on 9-10 March 2021. The conference will consist of panel discussions, company presentations, virtual events, and networking opportunities. The presentation will be available on demand during the conference. Investors can register for the conference here: https://hcwevents.com/globalconference/#toggle-id-1-closed
 
No new material information will be disclosed, and the presentations will be made available on the Company website shortly after the events here: http://www.reneuron.com/investors/presentations/
 
Contacts:
 



ReNeuron


www.reneuron.com/investors




Olav Hellebø, Chief Executive Officer


Via Walbrook PR




Michael Hunt, Chief Financial Officer


 




 


 




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Ben Maddison, Stewart Wallace


+44 (0)20 7710 7600
 














Allenby Capital Limited (Joint Broker)
James Reeve/George Payne (Corporate Finance)
Tim Sohal (Sales & Corporate Broking)


+44 (0)20 3328 5656




 


 




Walbrook PR (Media & Investor Relations) 


+44 (0)20 7933 8780 or reneuron@walbrookpr.com




Paul McManus, Alice Woodings


+44 (0)7980 541 893 / +44 (0)7407 804 654



 
About ReNeuron 
 
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.  
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com
  
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAUSABRARUUUAR